Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 36

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
	2,263,962

			1,981,155

			Total liabilities and shareholders' equity

			$
			4,164,181

			$
			3,813,982

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

3

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Operations

			Three Months Ended

			December 31, 2024

			December 31,2023

			Expenses:

			Research and development

			$
			1,019,818

			$
			704,458

			General and administrative

			878,871

			1,152,971

			Loss from operations

			(1,898,689
			)

			(1,857,429
			)

			Other income (loss):

			Reimbursement grant income

			301,195

			120,834

			Interest income

			1,666

			60,966

			Foreign exchange loss

			(21,425
			)

			(2,822
			)

			281,436

			178,978

			Net loss

			(1,617,253
			)

			(1,678,451
			)

			Exchange differences on translation

			18,656

			(572
			)

			Net comprehensive loss

			$
			(1,598,597
			)
			 
			$
			(1,679,023
			)

			Weighted average number of common shares

			3,345,135

			3,128,024

			Loss per common share - basic and diluted

			$
			(0.48
			)
			 
			$
			(0.54
			)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

4

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Cash Flows

			Three Months Ended

			December 31, 2024

			December 31,2023

			Cash flows from operating activities:

			Net loss

			$
			(1,617,253
			)